Pablo Alonso rubio, Spain
Presenter of 2 Presentations
DIFFERENCES IN GLUCOSE MONITORING DATA AND HEALTH-RELATED QUALITY OF LIFE IN CHILDREN AND TEENAGERS WITH TYPE 1 DIABETES ACCORDING TO GLYCEMIC CONTROL
- Pablo Alonso rubio, Spain
- Pilar Bahillo curieses, Spain
- Marta Murillo vallés, Spain
- Pablo Prieto matos, Spain
- Belén Huidobro fernández, Spain
- Amaia Rodríguez estévez, Spain
- Itxaso Rica echevarría, Spain
- SARA Herrero varas, Spain
- SARA Berrade zubiri, Spain
- María Montserrat Martín alonso, Spain
- Rebeca García garcía, Spain
- Laura Regueras santos, Spain
- Isolina Riaño-galán, Spain
Abstract
Background and Aims
Treatment with continuous subcutaneous insulin infusion (CSII) in children with type 1 Diabetes (DM1) may lead to changes in glucose monitoring data and health-related quality of life (HRQOL).
A study was designed to assess differences in glucose monitoring data and HRQOL according to HbA1c as indicator of glycemic control.
Methods
Glycemic metrics were recorded from glucose monitoring devices of 157 children aged 8 to 18, treated with CSII or multiple dose injection (MDI) in 8 Pediatrics Diabetes Units in Spain. These patients filled up DCGM-12 as HRQOL instrument. The patients were divided in three groups: patients with CSII and Hb1c < 7.5%, patients with CSII and HbA1c ≥ 7.5%, and patients with MDI.
Results
| Insulin pumps | MDI (n:103) | Statistical significance | ||
| HbA1c < 7.5% (n:40) | HbA1c ≥ 7.5% (n:14) | |||
| Χ ± SD | ||||
| Time in range: 70-180 mg/dl (%) | 62.51 ± 9.46 | 50.08 ± 15.16 | 57.37 ± 18.15 | 0.038 |
| Hyperglycemia > 180 mg/dl (%) | 31.37 ± 12.82 | 46.94 ± 19.51 | 39.72 ± 22.83 | 0.025 |
| Hypoglycemia < 70 mg/dl (%) | 8.05 ± 5.62 | 4.11 ± 4.98 | 6.54 ± 8.03 | 0.203 |
| DCGM-12. Range (0-100) | 81.46 ± 12.50 | 88.84 ± 8.75 | 79.81 ± 14.50 | 0.068 |
Conclusions
The patients treated with CSII whose HbA1c was less than 7.5% had bigger percentage of time in range and less time in hyperglycemia than the group with worse glycemic control.
Both groups of patients with CSII had bigger HRQOL than the patients treated with MDI but the group with CSII and better glycemic control had worse HRQOL than the other CSII group.
ARE THERE DIFFERENCES IN HEALTH-RELATED QUALITY OF LIFE IN CHILDREN AND TEENAGERS WITH TYPE 1 DIABETES BETWEEN INSULIN PUMP THERAPY AND MULTIPLE DOSE INJECTION THERAPY?
- Pablo Alonso rubio, Spain
- Pilar Bahillo curieses, Spain
- Pablo Prieto matos, Spain
- Belén Huidobro fernández, Spain
- Itxaso Rica echevarría, Spain
- Marta Murillo vallés, Spain
- Amaia Rodríguez estévez, Spain
- María Montserrat Martín alonso, Spain
- ELISABETH Burillo sánchez, Spain
- MARÍA JESÚS Chueca guindulain, Spain
- Rebeca García garcía, Spain
- Laura Regueras santos, Spain
- Isolina Riaño-galán, Spain
Abstract
Background and Aims
Type 1 Diabetes (DM1) in childhood and adolescence is a chronic disease that affects health related quality of life (HRQOL). HRQOL instruments can be used to evaluate the effect on the quality of life depending on therapy such as continuous subcutaneous insulin infusion (CSII) or multiple doses of insulin (MDI).
A study was designed to assess the differences in HRQOL in two groups of children and teenagers with DM1 according to treatment modality.
Methods
157 children and teenagers aged 8 to 18 years followed in 8 Pediatrics Diabetes Units in Spain, filled up two self-reported HRQOL instruments. These HRQOL instruments were the Spanish version of DISABKIDS Chronic generic measure (DCGM-12) and the DISABKIDS Diabetes Module. The DCGM-12 assesses the HRQOL globally in chronic conditions. The Diabetes Module is divided in an Impact and a Treatment scale. Sociodemographic and glycemic control data were recorded.
Results
There were not significant differences in sociodemographic factors, glycemic control, and HRQOL score between the two groups.
| MDI (n:103) | CSII (n:54) | Statistical significance | |
| Χ ± SD | Χ± SD | ||
| HbA1c (%) | 7.08 ± 0.90 | 7.00 ± 0.63 | 0.54 |
| DCGM-12 Range (0-100) | 79.81 ± 14.50 | 83.37 ± 12.02 | 0.12 |
| Impact Scale Range (0-100) | 61.04 ± 16.00 | 63.73 ± 15.07 | 0.31 |
| Treatment Scale Range (0-100) | 66.62 ± 24.56 | 70.49 ± 22.92 | 0.34 |
| Table 1: HRQOL according to treatment modality. | |||
Conclusions
The patients with CSII therapy had slightly better HRQOL score in DCGM-12 and in both specific scales of DM1 than the MDI group, but these differences were not statistically significant.